1. Immunotherapy 'Shock' with vitiligo due to nivolumab administration as third line therapy in lung adenocarcinoma
- Author
-
Aggeliki Rapti, Dimitrios Drougas, Chong Bai, Chrysa Sardeli, Haidong Huang, Liana Papaemmanouil, Christoforos Kosmidis, Dimitrios Hatzibougias, Paul Zarogoulidis, Wolfgang Hohenforst-Schmidt, Lemonia Veletza, Georgia Trakada, Anastasios Kallianos, and Theodora Tsiouda
- Subjects
0301 basic medicine ,Pulmonary and Respiratory Medicine ,Oncology ,medicine.medical_specialty ,medicine.medical_treatment ,Case Report ,Vitiligo ,Adenocarcinoma ,NSCLC ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,Adverse effect ,lcsh:RC705-779 ,Lung ,business.industry ,lcsh:Diseases of the respiratory system ,Immunotherapy ,medicine.disease ,Nivolumab ,030104 developmental biology ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,Shock (circulatory) ,EBUS ,medicine.symptom ,business ,Tyrosine kinase - Abstract
Non-small cell lung cancer is still diagnosed at late stage due to the lack of early symptoms and methods of diagnostic prevention. In the past ten years several targeted therapies have been introduced or explored. Tyrosine kinase inhibitors and immunotherapy are currently considered the most effective and safe therapies in comparison to the non-specific cytotoxic agents. Regarding tyrosine kinase inhibitors the adverse effects have been fully explored, however; on the other hand for immunotherapy there are still several issues to be clarified. We report a rare case of a patient with lung cancer adenocarcinoma who developed vitiligo throughout his body after nivolumab administration.
- Published
- 2017
- Full Text
- View/download PDF